Urticaria

Primary care physicians frequently encounter patients with acute-onset urticaria and angioedema; the prevalence in the United States population is 14 to 25 percent. (1) Caring for patients with these disorders becomes challenging when symptoms are severe, involve multiple organ systems, or recur over months or years. Diagnostic testing can be expensive and may not determine a cause. Patients may become anxious, fearing an undiagnosed illness, and physicians may become frustrated by the lack of data to determine an etiology.

Clinical Manifestations

Urticarial lesions are polymorphic, round or irregularly shaped pruritic wheals that range in size from a few millimeters to several centimeters (Figure 1). Lesions can develop anywhere on the body and are spread by scratching, combining into large, fiery-red patches. Sometimes a vascular steal phenomenon causes lesions to appear hyperemic in the center with a white halo along the circumference. (2)

Angioedema, which can occur alone or with urticaria, is characterized by nonpitting, nonpruritic, well-defined, edematous swelling that involves subcutaneous tissues (e.g., face, hands, buttocks, genitals), abdominal organs, or the upper airway (i.e., larynx). Angioedema tends to occur on the face and may cause significant disfigurement (Figure 2). Laryngeal angioedema is a medical emergency requiring prompt assessment. Acute intestinal and stomach swelling may mimic symptoms of an abdominal surgical emergency.

Chronology differentiates subcategories of urticaria. Wheal and flare reactions last fewer than six weeks in patients with acute urticaria, but chronic urticaria can persist for months or years. In a recent study, 47 percent of patients with chronic urticaria of unknown etiology had spontaneous remission after one year. (3) Patients with physical urticaria (i.e., lesions produced by physical stimuli) had more persistent disease, with only 16 percent undergoing spontaneous remission. (3)

Acute urticaria also is differentiated from chronic urticaria by ongoing or longstanding urticarial symptoms that trigger an IgE-mediated process. Chronic urticaria and angioedema tend to be idiopathic, with no identifiable cause, or to be precipitated by a multitude of endogenous or exogenous factors that can be immunologic or nonimmunologic (Table 1).

Clinical Evaluation and Pathogenesis

Evaluation of patients with urticaria begins with a thorough history that details travel, recent infection, occupational exposure, medications (prescription drugs and herbal and vitamin supplements), ingestion of foods, timing and onset of lesions, morphology, and associated symptoms. Family medical history, preexisting allergies, and exposure to physical stimuli should be documented. A comprehensive physical examination can uncover important diagnostic clues that may help diagnose comorbidities. Physicians should ensure that proper health maintenance testing is up to date and consider diagnostic testing directed by history and physical examination findings, especially in patients with chronic urticaria. (4,5)

Acute urticaria is self-limited and requires minimal laboratory evaluation. In asymptomatic patients with chronic urticaria and minimal history or physical examination findings, clinical practice guidelines suggest consideration of a complete blood count with differential, urinalysis, erythrocyte sedimentation rate, and liver function tests to screen for a medical condition. (4,5)

A recent systematic review of more than 6,000 patients with urticaria and angioedema found that routine laboratory screening tests independent of the patient's history and physical examination should be discouraged, because these tests are of little value in discovering the cause of the reactions. (6) [Recommendation level B, systematic review of lower quality trials] Clinical scenarios may offer diagnostic clues. For example, an IgE-mediated reaction would be suspected in patients with a history of acute urticaria within an hour after ingesting a food or drug. Skin testing or radioallergosorbent testing may document a causal relationship. (4)

Histamine released from cutaneous mast cells and basophils in response to inciting stimuli is the primary mediator of urticaria. In this process, specific IgE antibodies cross-link the IgE receptors bound to mast cells and stimulate the production of preformed and newly generated inflammatory mediators. Complement anaphylatoxins also may induce mast cell histamine release, as can certain medications or physical stimuli through direct nonimmunologic mast cell activation. (1,7)

IMMUNOLOGIC RESPONSES

Immunologic urticaria and angioedema are a result of IgE antibody-mediated reactions that usually occur within one hour of exposure to the allergen. Type I IgE-mediated allergic reactions can be caused by drugs (most notably penicillin and cephalosporin), insect venom, foods (e.g., fish, shellfish, eggs, nuts, legumes, milk, soy,wheat), preservatives, latex, and aeroallergens (e.g., dust mites, molds, pollens, animal dander). (4,8)

A rarer cause of acute urticaria is a type II hypersensitivity reaction mediated by cytotoxic antibodies and complement activation. An example is a transfusion reaction in which IgG and IgM anti-red-cell antibodies activate complement and cause cell lysis. (9) Serum sickness caused by drugs or proteins is an example of a type III hypersensitivity (antigen-antibody complex-mediated) reaction. Clinical presentation may include urticaria of several weeks' duration, arthralgias, fever, and glomerulonephritis. (8) Urticaria also has been associated with herpes virus, cytomegalovirus, Epstein-Barr virus, and chronic hepatitis infections, and with bacterial, fungal, and parasitic infections. (4,5,9) Patients with chronic urticaria

and a family history of thyroid disease may be at higher risk for Hashimoto's thyroiditis. (10)

Urticarial vasculitis should be considered if a single urticaria lesion lasts longer than 24 hours, if lesions are burning or painful, if they are more common in the lower extremities, and if they leave an area of hemosiderin pigment after they have resolved. (4,5,9) Infection, drug sensitivity, serum sickness, chronic hepatitis, hypocomplementemic urticarial vasculitis syndrome, and systemic lupus erythematosus may cause urticarial vasculitis. (11,12) A 4-mm punch biopsy may confirm neutrophilic infiltration consistent with leukocytoclastic vasculitis. Patients with urticarial vasculitis should be referred to a dermatologist for further evaluation and management, which may include immunomodulatory therapy to down-regulate the inflammatory response. (4,5,9)

NONIMMUNOLOGIC RESPONSES

Ingestion of certain foods, including strawberries, tomatoes, shrimp, lobster, cheese, spinach, and eggplant, also can trigger hives through direct mast cell degranulation. Several medications, including opiates (especially codeine and morphine), muscle relaxants (e.g., curare [Tubocurarine]), vancomycin (Vancocin), dextran, bile salts, nonsteroidal anti-inflammatory drugs, aspirin, and radiographic contrast media, may produce acuteonset wheal and flare reactions in susceptible patients. (4,9) Angioedema has been reported in patients taking angiotensin-converting enzyme inhibitors. (5) Patients with a rare inherited or acquired disorder linked to C1 esterase deficiency or autoimmune consumption may present with recurrent angioedema without urticaria.

Although most cases of urticaria and angioedema are idiopathic with benign courses, physicians should follow up on factors that might appear inconsequential at first but may prove to be worthy of further evaluation. Table 2 gives diagnostic clues from the clinical investigation and an associated rationale for the development of urticaria and angioedema.

Physical urticaria is triggered by environmental factors, such as pressure to the skin, heat or cold, exercise, sun or water exposure, and mechanical vibration. (1,9) Most patients with physical urticaria develop wheals and itching soon after contact with the offending stimuli. However, patients with delayed pressure urticaria develop symptoms two to eight hours after exposure to the pressure stimulus. Physicians should take a thorough history, keeping in mind that the patient may have more than one cause for urticaria. Challenge testing, which reproduces exposure to the suspected stimuli in a supervised clinical environment, can confirm the diagnosis.

Approach to Therapy

Treatment of urticaria should be directed at avoiding known triggering agents and alleviating associated symptoms. Patients should be advised to avoid alcoholic drinks and over-the-counter drugs such as aspirin or nonsteroidal anti-inflammatory drugs because they may aggravate the condition. (2,4) [Recommendation level C, expert opinion] Step therapy guidelines for pharmacotherapeutic management of chronic urticaria is given in Figure 3.

[FIGURE 3 OMITTED]

The mainstay of therapy for acute urticaria is a long-acting, nonsedating histamine [H.sub.1]-receptor antagonist such as fexofenadine (Allegra-D), desloratadine (Clarinex), or loratadine (Claritin). (5,8,13,14) [Reference 14--Recommendation level C, expert opinion] Cetirizine (Zyrtec) also is effective but may be mildly sedative and should be taken at night. The additive effect of a first-generation [H.sub.1]-receptor antagonist, such as hydroxyzine (Atarax, 10 to 50 mg nightly), with a second-generation [H.sub.1]-receptor antagonist is beneficial for its soporific effects and to alleviate nocturnal pruritus. (11) Because of the adjunctive effect of blocking both histaminic receptors, the addition of a histamine [H.sub.2]-receptor antagonist has shown benefit in the management of urticaria in controlled clinical studies. (2) Either cyproheptadine (Periactin) or the tricyclic antidepressant doxepin (Sinequan) in titrated dosages is beneficial as supplemental therapy for nocturnal pruritus and the associated anxiety that is common in patients with chronic urticaria and angioedema. (9)

Patients should be advised of possible carryover of cognitive effects when using sedating antihistamines at night. Leukotriene modifiers such as montelukast (Singulair, 10 mg daily) or zafirlukast (Accolate, 20 mg twice daily) may play a role in a select subgroup of patients with chronic urticaria, especially those with aspirin sensitivity. (15) Patients with a history of urticaria and angioedema or isolated angioedema episodes should be prescribed epinephrine in an auto-injectable instrument (EpiPen) in a dosage of 0.3 mg given intramuscularly in the thigh and be instructed in its proper use for laryngeal edema, bronchospasm, and hypotension. (16) [Recommendation level C, expert opinion]

Patients with unresponsive urticaria or angioedema should be referred to an allergist or dermatologist and may require a short-term course of oral glucocorticoids (e.g., oral prednisone, 10 to 20 mg daily). Investigative treatment using immunomodulatory therapies such as cyclosporine, plasmapheresis, and intravenous immunoglobulin have been shown to be beneficial in autoimmune chronic urticaria. (17-19)

The author indicates that she does not have any conflicts of interest. Sources of funding: none reported.

REFERENCES

(1.) Zacharisen MC. Pediatric urticaria and angioedema. Immunol Allergy Clin North Am 1999; 19:363-82.

(2.) Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000;105:664-72.

(3.) Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001;45:387-91.

(4.) Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter. Part I: acute urticaria/angioedema. Part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000;85:521-44.

(5.) Charlesworth EN. Urticaria and angioedema: a clinical spectrum. Ann Allergy Asthma Immunol 1996; 76:484-95.

(6.) Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: a systematic review. J Am Acad Dermatol 2003;48:409-16.

(7.) Prussin C, Metcalfe DD. 4. IgE, mast cells, basophils, and eosinophils [Published erratum appears in J Allergy Clin Immunol 2003;112:267]. J Allergy Clin Immunol 2003;111(2 suppl):S486-94.

(8.) Kennedy MS. Evaluation of chronic eczema and urticaria and angioedema. Immunol Allergy Clin North Am 1999;19:19-33.

(9.) Grattan CE, Charlesworth EN. Urticaria. In: Holgate ST, Church M, Lichtenstein LM. Allergy. 2d ed. London: Mosby, 2001:93-104.

(10.) Zauli D, Deleonardi G, Foderaro S, Grassi A, Bortolotti R, Ballardini G, et al. Thyroid autoimmunity in chronic urticaria. Allergy Asthma Proc 2001; 22:93-5.

(11.) Fox RW. Chronic urticaria: mechanisms and treatment. Allergy Asthma Proc 2001;22:97-100.

(12.) Black AK. Urticarial vasculitis. Clin Dermatol 1999;17:565-9.

(13.) Kaplan AP. Clinical practice: chronic urticaria and angioedema. N Eng J Med 2002;346:175-9.

(14.) Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001;2:27-32.

(15.) Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998;102:876-7.

(16.) Safdar B, Cone DC, Pham KT. Subcutaneous epinephrine in the prehospital setting. Prehosp Emerg Care 2001;5:200-7.

(17.) Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002;46:645-57.

(18.) Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001;44:1010-24.

(19.) Blauvelt A, Hwang ST, Udey MC. 11. Allergic and immunologic diseases of the skin. J Allergy Clin Immunol 2003;111(2 suppl):S560-70.

BARBARA A. MULLER, M.D., is professor of clinical medicine, senior assistant hospital director, and assistant dean at the University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City. Dr. Muller completed medical training at the Autonomous University of Guadalajara in Guadalajara, Mexico, postgraduate training at Hackensack (N.J.) Medical Center, and a fellowship in allergy-immunology at the University of Iowa Hospitals and Clinics, Iowa City.

Address correspondence to Barbara A. Muller, M.D., Department of Internal Medicine, Division of Allergy-Immunology, BT 1081 GH, University of Iowa Health Care, 200 Hawkins Dr., Iowa City, IA 52242-1081. Reprints are not available from the author.

COPYRIGHT 2004 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group